Reviewer's report

Title: Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

Version: Date: 7 December 2013

Reviewer: Ondrej Dolezal

Reviewer's report:

Article is providing sufficient information and guidelines for treatment in MENA region; however seems to be purely literature overview, missing original data. It will be extremely helpful to provide more information about regional differences if any.

Major compulsory revisions:
1. Mentioning "literature overview" in the title would be beneficial
2. Some graphs/figures are copied from Tysabri (Natalizumab) Benefit/Risk Update provided by Biogen Idec on regular basis (namely Fig. 1 and Fig.2) and permission to do so from the above company is not mentioned.

Minor essential revisions:
1. Is it possible to provide more information about prevalence and incidence of MS in the region or in any particular country (if data available), about percentage of highly active MS in the region, about any experience with Tysabri or PML if any etc.?
2. Current practice, current treatments used in highly active disease (MTX, CPA etc.)?

Discretionary Revisions:
1. From the context I understood that McDonald’s diagnostic criteria are used in the region however not explicitly mentioned.

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:
Travel grant Biogen idec, Novartis, speaking honoraria Merck/Serono